Navigation Links
iPierian Appoints Dr. Chad Cowan and Dr. Konrad Hochedlinger to Scientific Advisory Board
Date:8/6/2009

SOUTH SAN FRANCISCO, Calif., Aug. 6 /PRNewswire/ -- iPierian, Inc., a biopharmaceutical company focused on changing the paradigm of drug discovery and development through the application of cellular reprogramming, today announced the appointments of Dr. Chad Cowan and Dr. Konrad Hochedlinger to the company's Scientific Advisory Board (SAB).

"Drs. Cowan and Hochedlinger are leading scientists in stem cell research and their addition to the iPierian SAB rounds out an exemplary group of scientists. The collective expertise of this SAB will further our efforts of developing disease-relevant models to discover drugs, and translating these efforts into new therapies for patients," said John P. Walker, chief executive officer of iPierian.

Dr. Chad Cowan is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, and assistant investigator at Stowers Medical Institute. His research focuses on adipogenesis, metabolic disease, and the impact of environmental and genetic factors on the development of disease.

Dr. Konrad Hochedlinger is assistant professor of Medicine at Harvard Medical School and the Department of Stem Cell and Regenerative Biology, principal faculty member at the Harvard Stem Cell Institute and investigator at the Massachusetts General Hospital Cancer Center and Center for Regenerative Medicine. Dr. Hochedlinger is a leader in reprogramming technology and produced the first transgene-free induced pluripotent stem (iPS) cells. Most recently, Dr. Hochedlinger received the International Society for Stem Cell Research (ISSCR) Outstanding Young Investigator Award.

About iPierian

iPierian is a South San Francisco-based biopharmaceutical company focused on the industrialization of induced pluripotent stem cell (iPS) technology with the mission of creating new therapeutics through cellular reprogramming and directed differentiation of patient cells. iPierian is backed by Kleiner Perkins Caufield & Byers, Highland Capital Partners, MPM Capital and FinTech Global Capital. The initial focus of the company is in neurodegeneration, particularly spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS) and Parkinson's disease as well as in cardiovascular disease, where iPierian has a collaboration with The Gladstone Institute of Cardiovascular Disease and Dr. Deepak Srivastava, the institute's director. iPierian plans to enhance its partnership efforts to further expand into metabolic diseases. Earlier this year, the company announced a formal collaboration with the laboratory of Dr. Shinya Yamanaka of Kyoto University to develop and improve methods of deriving iPS cell lines in order to advance iPS cell technology.

Because iPS cells are believed to be able to grow indefinitely in culture and to differentiate into many cell types, iPS cells have great potential for disease research, preclinical drug testing and cell-based therapy. iPierian's approach places the patient at the forefront of the drug discovery process in order to reduce drug development time and increase the probability of success for drug candidates. iPierian plans to use precise human disease models to find new molecular targets and develop proprietary therapeutic small molecule or biologic drugs for its own pipeline to treat specific diseases.


'/>"/>
SOURCE iPierian, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Streamline Health Appoints Jon Phillips Chairman of the Board of Directors
2. Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
3. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
4. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
5. Sunesis Pharmaceuticals Appoints Helen S. Kim to Board of Directors
6. Red Cross Appoints Peggy Dyer as Chief Marketing Officer
7. MonoSol Rx Appoints Theodore Clemente Vice President Business Development
8. WuXi PharmaTech Appoints Dr. Chi-Chung Chan as Vice President of Pharmacology
9. Webmedx Appoints New Senior Vice President of Client Development, Chris Cashwell
10. Immucor Appoints Chief Operating Officer
11. DaVita Clinical Research Appoints Mahesh Krishnan as Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is ... than filling out a survey; in many cases health professionals and patients are working ... and research on the importance of active engagement with patients and members of the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & Associates ... special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to date ... elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded by ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: